SCHEDULE 13G/A 0001104659-22-074786 0001030617 XXXXXXXX LIVE 1 Common stock, par value $0.000005 per share 12/31/2024 0001357874 PRECISION BIOSCIENCES INC 74019P207 302 EAST PETTIGREW STREET SUITE A-100 DURHAM NC 27701 Rule 13d-1(c) Novartis Pharma AG V8 0.00 413581.00 0.00 413581.00 413581.00 N 5.4 CO Novartis AG V8 0.00 413581.00 0.00 413581.00 413581.00 N 5.4 HC CO PRECISION BIOSCIENCES INC 302 EAST PETTIGREW STREET SUITE A-100, DURHAM, NC, 27701 This statement is filed on behalf of the following persons with respect to the shares of Common Stock of the Issuer: (i) Novartis Pharma AG., a Swiss corporation ("Novartis Pharma"), with respect to shares held by it; and (ii) Novartis AG, a Swiss corporation ("Novartis"), as the publicly-owned parent of Novartis Pharma, with respect to the shares held by Novartis Pharma. The foregoing persons are hereinafter referred to collectively as the "Reporting Persons." The address of the principal business offices of the Reporting Persons is Lichtstrasse 35, CH-4056 Basel, Switzerland. Novartis Pharma is a corporation organized under the laws of Switzerland and is a direct wholly-owned subsidiary of Novartis. Novartis is a corporation organized under the laws of Switzerland and is the publicly-owned parent of Novartis Pharma. Y The information required by Items 4(a)-(c) with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 7,671,059 outstanding shares of Common Stock, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2024. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1 - Evidence of Signatory Authority Novartis Pharma AG /s/ Christian Rehm 02/12/2025 /s/ Lukas Foertsch 02/12/2025 Novartis AG /s/ Christian Rehm 02/12/2025 /s/ Daniel Weiss 02/12/2025